HiftR.J., PetersT.J., et al. (2012). A review of the clinical presentation, natural history and inheritance of variegate porphyria: its implausibility as the source of the 'Royal Malady.' J. Clin. Pathol., 65, 200–205.
2.
MacalpineI., and HunterR. (1966). The “insanity”. of King George 3d: a classic case of porphyria. Br. Med. J., 1, 65–71.
3.
MacalpineI., HunterR., et al. (1968). Porphyria in the royal houses of Stuart, Hanover, and Prussia. A follow-up study of George 3d's illness. Br. Med. J., 1, 7–18.
4.
PanedaM.A., Lopez-FrancoE., et al. (2013). Safety and liver transduction efficacy of rAAV5-cohPBGD in non-human primates: A potential therapy for Acute Intermitent Porphyria. Hum. Gene Ther. [Epub ahead of print]; DOI: 10.1089/hum.2013.166.
5.
RohlJ.C.G., WarrenM., et al. (1999). Purple Secret: Genes, 'Madness,' and the Royal Houses of Europe. Transworld Publishers, Ltd., London.
6.
SoonawallaZ.F., OrugT., et al. (2004). Liver transplantation as a cure for acute intermittent porphyria. Lancet, 363, 705–706.
7.
UnzuC., SampedroA., et al. (2010). Porphobilinogen deaminase over-expression in hepatocytes, but not in erythrocytes, prevents accumulation of toxic porphyrin precursors in a mouse model of acute intermittent porphyria. J. Hepatol., 52, 417–424.
8.
UnzuC., SampedroA., et al. (2011). Sustained enzymatic correction by rAAV-mediated liver gene therapy protects against induced motor neuropathy in acute porphyria mice. Mol. Ther., 19, 243–250.
9.
YasudaM., BishopD.F., et al. (2010). AAV8-mediated gene therapy prevents induced biochemical attacks of acute intermittent porphyria and improves neuromotor function. Mol. Ther., 18, 17–22.
